Tag: Gilead Sciences Inc
Lenacapavir by Gilead demonstrates 96% reduction in HIV infections in clinical trial.
A recent study has shown that Gilead’s new HIV prevention injectable drug, lenacapavir, has proven to reduce HIV infections by 96%. This positive phase-three trial data indicates the potential approval
DetailMidday Stock Market Update: Kroger, Petco, Moderna, and Roku Stocks Soaring
Shares of Kroger, the supermarket chain, surged over 4% in midday trading following the release of their mixed fiscal second-quarter results. Despite revenue falling short of expectations, Kroger reported adjusted
Detail